Close

RedHill announces launch of Talicia in UAE to treat bacterial infection

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Alexion and DHL Partner for 100% Sustainable Aviation Fuel

Dublin, Alexion, AstraZeneca Rare Disease, has partnered with DHL...

Why Early Intervention Is Key To Managing Chronic Health Concerns

Proactive health management is essential for maintaining a good...

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

RedHill Biopharma Ltd. , a specialty biopharmaceutical company announced the launch of Talicia (omeprazole magnesium, amoxicillin and rifabutin) in the United Arab Emirates (UAE) – making it available by prescription to treat adults with Helicobacter pylori (H. pylori) infection. The commercial launch of Talicia in the UAE triggers RedHill’s eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales. Talicia is the first approved low-dose rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori.

“We are delighted with the commercial launch of Talicia in the UAE, bringing this important medicine to patients in the region,” said Rick Scruggs, President, RedHill Biopharma Inc. & Chief Commercial Officer. “As one of the strongest risk factors for gastric cancer, H. pylori is a major public health concern. With 41% of the UAE population infected by H. pylori and the alarming failure rates of clarithromycin-based therapies there is a significant medical need for a highly effective first-line H. pylori therapy. Our efforts to make Talicia available to patients in more countries continue as we work to explore additional opportunities with existing and potential partners.”

Clarithromycin-based triple therapy continues to wane in effectiveness. A 2021 study demonstrated only 68.5% eradication with traditional clarithromycin-based triple therapy, which declined further to 32% in patients harboring resistant H. pylori organisms. Clarithromycin-based treatment efficacy can also be negatively impacted by patient obesity or diabetic status, neither of which impact Talicia’s safety or efficacy, according to data from post-approval post-hoc analysis.

Latest stories

Related stories

Alexion and DHL Partner for 100% Sustainable Aviation Fuel

Dublin, Alexion, AstraZeneca Rare Disease, has partnered with DHL...

Why Early Intervention Is Key To Managing Chronic Health Concerns

Proactive health management is essential for maintaining a good...

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back